- Home
- HBAN vs BIIB Comparison
HBAN vs BIIB Comparison
Compare HBAN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBAN | BIIB |
|---|---|---|
| Founded | 1866 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 24.2B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | HBAN | BIIB |
|---|---|---|
| Price | $17.73 | $173.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 22 |
| Target Price | $19.28 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 27.6M | 2.0M |
| Earning Date | 01-16-2026 | 10-30-2025 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ 38.74 | N/A |
| EPS | 1.43 | ★ 10.97 |
| Revenue | $7,502,000,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $20.87 | $3.61 |
| Revenue Next Year | $30.73 | N/A |
| P/E Ratio | ★ $12.30 | $15.48 |
| Revenue Growth | ★ 12.14 | 4.77 |
| 52 Week Low | $11.92 | $110.04 |
| 52 Week High | $18.04 | $185.17 |
Technical Indicators
Market Signals| Indicator | HBAN | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 68.34 | 53.21 |
| Support Level | $17.51 | $168.56 |
| Resistance Level | $17.91 | $175.94 |
| Average True Range (ATR) | 0.33 | 5.21 |
| MACD | 0.05 | -1.78 |
| Stochastic Oscillator | 81.06 | 34.76 |
Price Performance
Historical ComparisonAbout HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with around $208 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).